| ¿µ¹® | gene | ÇÑ±Û | À¯ÀüÀÚ |
|---|---|---|---|
| ¼³¸í | À¯ÀüÀÚ´Â ±æ°Ô ¶ì¸¦ Çü¼ºÇÑ DNAºÐÀÚÀÇ ÀϺκÐÀ¸·Î ÇÑ °¡Áö ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °®Ãá ±â´ÉÀûÀÎ ´ÜÀ§ÀÌ´Ù. ¿¹¸¦ µé¾î Àν¶¸°À̶ó´Â ¹°ÁúÀÇ À¯ÀüÀÚ¶ó°í ÇÏ¸é »ç¶÷ÀÇ ¼¼Æ÷³»¿¡ ÀÖ´Â ±ä DNA ºÐÀÚ Áß¿¡¼ Àν¶¸°À̶ó´Â ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °¡Áö°í ÀÖ´Â ÇÑ ºÎºÐÀ» °¡¸®Å°´Â ¸»ÀÌ´Ù. °íÀüÀûÀÎ »ý¹°Çп¡¼´Â À¯ÀüÀÚ°¡ Ç¥ÇöÇüÀ» °áÁ¤Çϰųª ÁöÁ¤ÇÏ´Â ¿°»öüÀÇ ÀϺκÐÀ̶ó°í Á¤ÀǵǾúÁö¸¸, ¿À´Ã³¯¿¡´Â À¯ÀüÀÚ¿¡ ´ëÇØ¼ ºÐÀÚÀû Á¤Àǰ¡ Á¦¾ÈµÇ°í ÀÖÀ¸¸ç ±× Á¤ÀÇ´Â ÇϳªÀÇ À¯ÀüÀÚ´Â ÇϳªÀÇ È¿¼Ò¸¦ °áÁ¤ ¶Ç´Â ¾ÏÈ£ÈÇÏ´Â À¯Àü¹°ÁúÀÇ ÀϺκÐÀ̶ó´Â °³³äÀ¸·Î À̰ÍÀÌ À̸¥¹Ù 1°³ÀÇ À¯ÀüÀÚ 1°³ È¿¼Ò°¡¼³(one gene-one enzyme hypothesis)ÀÌ´Ù. Áï 1°³ÀÇ À¯ÀüÀÚ´Â 1°³ÀÇ È¿¼Ò¸¦ Á¦ÀÛÇϴµ¥ ÇÊ¿äÇÑ À¯ÀüÁ¤º¸¸¦ °¡Áø´Ù´Â °ÍÀÌ´Ù. ÇöÀç ÀÌ °¡¼³ÀÌ ¹Þ¾Æµé¿©Áö°í ÀÖ´Ù. |
||
| ¿µ¹® | gene therapy | ÇÑ±Û | À¯ÀüÀÚ¿ä¹ý |
|---|---|---|---|
| ¼³¸í | À¯Àüº´À» Ä¡·áÇÒ ¸ñÀûÀ¸·Î, Á¤»óÀûÀ¸·Î ±â´ÉÇÏ´Â ´ÜÀÏÀ¯ÀüÀÚ È¤Àº º¹¼öÀ¯ÀüÀÚ¸¦ ¾î¶² ±â¿ø¿¡¼ ¾ò¾î³»¾î »ý¼¼Æ÷¿¡ µµÀÔÇÏ´Â °Í. À¯Àü¹°ÁúÀº À¯ÀüÀÚ»ðÀÔ Á¶ÀÛ¿¡ ÀÇÇØ ¼ö¿ë¼¼Æ÷¿¡·Î µµÀԵȴÙ. Áï, À¯ÀüÀÚ¸¦ ³¢¿ö ³ÖÀº »õ·Î¿î ¼¼Æ÷¸¦ »ç¿ëÇÏ´Â Ä¡·á·Î¼ 1980³â ¹Ì±¹ÀÇ ÇÐÀÚ°¡ ÁöÁßÇØºóÇ÷ȯÀÚ¿¡°Ô °ÇàÇÏ¿© ºñÆÇÀ» ¹Þ¾ÒÁö¸¸, ¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¼Ò´Â 1990³â 9¿ù ¾Æµ¥³ë½Å µ¥¾Æ¹Ì³ª¾ÆÁ¦(adenosine deaminase, ADA) °áÇÌÁõ ȯÀÚÀÇ ¸²ÇÁ±¸¿¡ ADA À¯ÀüÀÚ¸¦ ³¢¿ö ³Ö´Â Ä¡·á¸¦ ½ÃÀÛÇÑ ÀÌ·¡ ÇöÀç´Â ¾ÏÀ» Æ÷ÇÔÇÑ ¸¹Àº Áúº´µéÀ» Ä¡·áÇÏ´Â ¸ñÀûÀ¸·Î ¾²ÀδÙ. |
||
| TAX | Taxol |
|---|---|
| TEFRA | Tax Equity and Fiscal Responsibility Act |
| CGRP | Calcitonin Gene Related Peptide(Protein) |
| CGRPs | Calcitonin Gene-Related Products |
| GnRH | Gonadotropin Releasing Hormone [HP 1898, 2034] = LHRH = Go... |
| TAX | Paclitaxel |
|---|---|
| 16S rDNA | 16S rRNA gene |
| PGK | 3-phosphoglycerate kinase gene |
| CGRP | AM/calcitonin gene-related peptide |
| alpha-CGRP | Alpha calcitonin gene-related peptide |
| gene products, tax | Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr. (12 Dec 1998) |
|---|---|
| income tax | Tax on the net income of an individual, organization, or business. (12 Dec 1998) |
| investment tax credit | A specified percentage of the dollar amount of certain new investments that a company can deduct as a credit against its income tax bill. (05 Dec 1998) |
| tax equity and fiscal responsibility act | Pl97-248. Title II of the act specifies "provisions relating to savings in health and income security programs." this includes changes in payment for services, benefits and premiums of medicare as well as changes in provisions under medicaid and other specific programs covered by social security. Title II includes various revenue measures. (12 Dec 1998) |
| tax exemption | Status not subject to taxation; as the income of a philanthropic organization. Tax-exempt organizations may also qualify to receive tax-deductible donations if they are considered to be nonprofit corporations under section 501(c)3 of the united states internal revenue code. (12 Dec 1998) |
| allelic gene | See: allele, dominance of traits. (05 Mar 2000) |
| antibiotic resistance gene | Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it. (09 Oct 1997) |
| autosomal gene | A gene located on any chromosome other than the sex chromosomes (X or Y). (05 Mar 2000) |
| bicoid gene | A group of genes which are important to the proper development of the head and thorax in the embryo of the fruit fly Drosophila melanogaster. (09 Oct 1997) |
| BRCA1 breast cancer susceptibility gene | This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer. (12 Dec 1998) |
| calcitonin gene-related peptide | <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response. It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator. Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion. Acronym: CGRP (05 May 2002) |
| cancer susceptibility gene | tumour suppressor gene |
| rab gene | 1. <molecular biology> One of the three main groups of ras like genes specifying small GTP-binding proteins (the others are ras and rho). Rab proteins are involved in vesicular traffic and seem to control translocation from donor to acceptor membranes. 2. <cell biology> Gene family in plants responsive to abscisic acid: encode proteins of 15-17 kD. (18 Nov 1997) |
| pair rule gene | <molecular biology> A segmentation gene, expressed sequentially between gap genes and segment polarity genes. In development of Drosophila, a set of about 8 genes that are expressed only in alternate segments (odd or even) of the developing embryo. Loss of function mutants thus lack alternate segments. Examples: even skipped (eve), fushi tarazu (ftz), hairy. (18 Nov 1997) |
| variable gene | <molecular biology> Those regions in the amino acid sequence of both the heavy and the light chains of immunoglobulins where there is considerable sequence variability from one immunoglobulin to other of the same class, in contrast to constant sequence (C) regions. The V regions are associated with the antigen binding areas. They contain hypervariable regions of particularly high sequence diversity. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|